CAJ | 학술논문

胰腺恶性肿瘤预后差，5年生存率不足5%。如何改善胰腺恶性肿瘤的治疗效果是目前国内外医学研究关注的焦点。随着对胰腺癌发病相关分子机制的深入研究，目前已经证实基因突变，如癌基因KRAS2，抑癌基因Cdkn2a、TP53等，是胰腺癌发生的重要标志。因此进一步了解胰腺癌发病的相关分子机制，研究新的治疗策略是十分重要的。本文就近年来国内、外针对胰腺癌细胞信号传导机制的研究做如下综述。
이선악성종류예후차，5년생존솔불족5%。여하개선이선악성종류적치료효과시목전국내외의학연구관주적초점。수착대이선암발병상관분자궤제적심입연구，목전이경증실기인돌변，여암기인KRAS2，억암기인Cdkn2a、TP53등，시이선암발생적중요표지。인차진일보료해이선암발병적상관분자궤제，연구신적치료책략시십분중요적。본문취근년래국내、외침대이선암세포신호전도궤제적연구주여하종술。
Pancreatic cancer has a very poor prognosis, with a five-year survival less than 5%. Nowadays, to improve the treat-ment efficacy of pancreatic cancer has been a highlight for medical researchers worldwide. Increasing knowledge about the molecular pathogenesis of the disease has shown that genic mutations, such as oncogene Kras2, and anti-oncogenes Cdkn2a, and TP53, are hall-marks of pancreatic cancer. Therefore, it is vital to deeply understand the pathogenetic mechanism of pancreatic cancer and find new therapeutic strategies to cover it. In this review, we summarized the recent advances in the signaling pathways of pancreatic cancer.